Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Amerikaanse aandelen Terug naar discussie overzicht

Gevo Inc.

2.510 Posts
Pagina: «« 1 ... 103 104 105 106 107 ... 126 »» | Laatste | Omlaag ↓
  1. [verwijderd] 5 maart 2017 19:05
    quote:

    hosternokke schreef op 2 maart 2017 12:55:

    [...]
    De cou lyp'ard en ville.
    Ceci n'est pas francais, c'est hollandais:

    De koe liep hard en viel.

    En dan snel en met een franse tongval uitspreken.
    Voilà.
    De Fransoos denkt dat ie 't niet goed verstaan heeft.
    De Hollander denkt dat ook of denkt dat z'n taalkennis niet zo ver reikt.
    Maar allebei knikken ze van ja en doen verder het zwijgen toe.

    Bonne soirée.
  2. forum rang 10 DeZwarteRidder 6 maart 2017 16:02
    quote:

    doewap schreef op 6 maart 2017 15:58:

    finance.yahoo.com/news/gevo-ranked-10...
    Whatever
    Gruber is een echte grapjas:

    “We are honored to be recognized by our peers and The Digest. I believe this award highlights the hard work and progress we have made over the past year towards our goal of becoming the leading producer of renewable isobutanol, alcohol-to-jet fuel (ATJ) and isooctane. I want to thank all of our customers, stockholders and employees for their ongoing support,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer.
  3. [verwijderd] 20 maart 2017 15:39
    www.aircargonews.com/0317/030317/Long...

    Het artikel is nogal 'biased' in het voordeel van Scandinavische ondernemingen zoals Neste en geeft geen accurate schets van de status van ATJ.

    Zowel productie als certificering daarvan is veel verder dan gesuggereerd wordt. En waar in dit artikel HEFA als meest kosten-effectief gezien wordt, stelt Gevo uiteraard dat ATJ beter is.
  4. forum rang 10 DeZwarteRidder 7 april 2017 10:13
    Gevo Reports Fourth Quarter 2016 Financial Results
    GlobeNewswire•March 29, 2017

    - Gevo to Host Conference Call Today at 4:30 p.m. EST/2:30 MST -

    Reports net loss per share of ($0.33) for the quarter
    Reports non-GAAP adjusted net loss per share1 of ($1.14) for the quarter
    Ended the quarter with cash and cash equivalents of $27.9 million
    Reports revenue of $5.8 million for the quarter
    Reports loss from operations of $6.5 million for the quarter
    Reports non-GAAP cash EBITDA loss2 of $4.7 million for the quarter

    ENGLEWOOD, Colo., March 29, 2017 (GLOBE NEWSWIRE) -- Gevo, Inc. (GEVO) today announced financial results for the three months ended December 31, 2016. Key highlights for the fourth quarter of 2016 and key subsequent events included:

    Gevo produced approximately 190,000 gallons of isobutanol during the quarter at Gevo’s isobutanol production facility located in Luverne, Minnesota (the “Agri-Energy Facility”).
    Cash and Cash Equivalents at February 28, 2017 were $22.6 million and the total principal face value of the debt outstanding was $17.7 million3.
    On February 13, 2017, Gevo signed a letter of intent with HCS Holding GmbH (HCS) to supply isooctane under an offtake agreement. HCS is a manufacturer of specialty products and solutions in the hydrocarbons sector, operating under such brands as Haltermann Carless. In the first phase of the contemplated binding offtake agreement, HCS is expected to purchase isooctane produced at Gevo’s demonstration hydrocarbons plant located in Silsbee, Texas, commencing in 2017. During the first phase, expected revenue would be in the range of $2-3 million per year and would continue until completion of Gevo’s future, large-scale commercial hydrocarbon plant. In the second phase, HCS is expected to purchase approximately 300,000 to 400,000 gallons of isooctane per year under the contemplated binding offtake agreement for a period of five years. Gevo expects to supply this isooctane from its first large-scale commercial hydrocarbons facility, which is likely to be built at the Agri-Energy Facility.
    On February 13, 2017, the holder of Gevo’s 10% Convertible Senior Notes, due 2017 (the “2017 Notes”), agreed to extend the maturity date of the 2017 Notes from March 15, 2017 to June 23, 2017 (the “2017 Notes Extension Transaction”). The terms of the 2017 Notes Extension Transaction included, among other things, the following: (i) an increase in the coupon on the 2017 Notes by two percent (2%) to twelve percent (12%); and (ii) the requirement that Gevo pay down $8 million of principal on the 2017 Notes as follows: $2 million on each of March 13, 2017, April 13, 2017, May 12, 2017 and June 13, 2017, with an option for Gevo to prepay all $8 million at any time in our sole discretion. In addition, as part of the 2017 Notes Extension Transaction, Gevo agreed to pay the holder fifteen percent (15%) of the net proceeds from its next underwritten public offering, completed prior to June 23, 2017, to be used to reduce the then-outstanding principal of the 2017 Notes.
    On February 17, 2017, in an underwritten offering Gevo sold 5,680,000 Series G units, with each Series G unit consisting of one share of common stock, a Series K warrant to purchase one share of common stock and a Series M warrant to purchase one share of common stock. Gevo also sold 570,000 Series H units, with each Series H unit consisting of a pre-funded Series L warrant to purchase one share of common stock, a Series K warrant to purchase one share of common stock and a Series M warrant to purchase one share of common stock. The gross proceeds from this offering were approximately $11.9 million, not including any future proceeds from the exercise of the warrants.
    On February 23, 2017, Gevo paid down the principal balance on the 2017 Notes with 15% of the net proceeds from the offering referred to above, along with the $8.0 million in prepayments under the supplemental indenture, for an aggregate total payment of $9.6 million, which reduced the principal balance on the 2017 Notes to approximately $16.5 million.
    In December 2016 and January 2017, Gevo entered into private exchange agreements with holders of its 7.5% convertible senior notes due 2022 (the “ 2022 Notes”) to exchange an aggregate of $9.8 million of principal amount of 2022 Notes for an aggregate of 2,407,214 shares of common stock. These exchanges reduced the outstanding principal amount of the 2022 Notes to $1.175 million.

    Outlook for 2017

    Gevo has established the following specific operational and financial targets and milestones for 2017:

    Restructure Gevo’s balance sheet in a manner that addresses the $17.7 million of debt represented by its outstanding convertible notes and that allows Gevo to execute on its long-term strategy and business development plan.
    Obtain binding supply contracts for a combination of isobutanol and related hydrocarbon products equal to at least fifty percent (50%) of the capacity of the expanded Agri-Energy Facility that Gevo plans to construct (the “Agri-Energy Facility Expansion”).
    Gevo estimates that its maximum annual isobutanol production capacity at the Agri-Energy Facility to be currently over 1 million gallons per year. As described below, however, Gevo expects to produce isobutanol at levels that better match market development sales in 2017. As such, Gevo expects to produce approximately 500,000 gallons of isobutanol during 2017.
    Achieve a cash EBITDA loss of between $18.0-$20.0 million for the fiscal year ending December 31, 2017.4
2.510 Posts
Pagina: «« 1 ... 103 104 105 106 107 ... 126 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.074
AB InBev 2 5.521
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.745
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.753
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.883
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.083
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.932
Allfunds Group 4 1.501
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.390
AMG 971 133.702
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.785
Arcelor Mittal 2.034 320.776
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.273
ASML 1.766 108.133
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 510
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.687
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404

Macro & Bedrijfsagenda

  1. 04 maart

    1. Nedap Q4-cijfers
    2. TKH Q4-cijfers
    3. Recticel Q4-cijfers
    4. Allfunds Q4-cijfers
    5. Werkloosheid januari (eur)
    6. Best Buy Q4-cijfers
    7. Pharming - Bava
    8. Atenor Q4-cijfers
  2. 05 maart

    1. Inkoopmanagersindex diensten februari def. (Jap)
    2. Inkoopmanagersindex diensten Caixin februari (Chi)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht